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Levodopa possesses antinociceptive actions against several somatic pain conditions. However, we do not
know at this moment whether levodopa is also effective to visceral pain. The present study was therefore
performed to clarify whether levodopa is effective to visceral pain and its mechanisms. Visceral sensation
was evaluated by colonic distension-induced abdominal withdrawal reﬂex (AWR) in conscious rats.
Subcutaneously (80 mg/rat) or intracisternally (2.5 mg/rat) administered levodopa signiﬁcantly
increased the threshold of colonic distension-induced AWR in conscious rats. The dose difference to
induce the antinociceptive action suggests levodopa acts centrally to exert its antinociceptive action
against colonic distension. While neither sulpiride, a D2 dopamine receptor antagonist, nor SCH23390, a
D1 dopamine receptor antagonist by itself changed the threshold of colonic distension-induced AWR, the
intracisternally injected levodopa-induced antinociceptive action was signiﬁcantly blocked by pre-
treatment with subcutaneously administered sulpiride but not SCH23390. Treatment with intracisternal
SB334867, an orexin 1 receptor antagonist, signiﬁcantly blocked the subcutaneously administered
levodopa-induced antinociceptive action. These results suggest that levodopa acts centrally to induce an
antinociceptive action against colonic distension through activation of D2 dopamine receptors and the
orexinergic system in the brain.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Levodopa is the drug to treat for Parkinson's disease (PD) (1) and
also used clinically for the relief of pain from bone metastasis (2),
pain induced by diabetic neuropathy and helps zoster (3,4). In
experimental animals, levodopa induced an analgesic action. Shi-
mizu et al. have demonstrated that intrathecal injection of levodopa
attenuated the substance-P-induced nociceptive behavior in mice
(5). Cobacho et al. (6) have shown an antiallodynic action of intra-
thecal levodopa in a rat model of painful mononeuropathy. Thus
clinical and experimental studies have suggested that levodopa
possesses antinociceptive actions against several somatic pain
conditions.: þ81 166 68 2846.
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. Production and hosting by ElseVisceral pain sensation is also known as one of vital sensory
functions. For example, visceral hypersensitivity reﬂected by
enhanced perception of physiological signals from the gut is
commonly considered to play amajor role in the pathophysiology of
functional gastrointestinal disorders such as irritable bowel syn-
drome (IBS) (7e10). It has been reported that the same chemical is
not necessarily capable of reducing not only somatic pain but
visceral pain because Ide et al. (11) have showed that ()-Pentazo-
cine induces visceral chemical antinociception, but not thermal,
mechanical, or somatic chemical antinociception, in m-opioid re-
ceptor knockout mice. Since the association between levodopa and
visceral pain perception has not been investigated while levodopa
does possess antinociceptive actions against somatic pain condi-
tions as described above, the present studywas thereforeperformed
to clarify whether levodopa is also effective to visceral pain and its
mechanisms.vier B.V. This is an open access article under the CC BY-NC-ND license (http://
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2.1. Animals
Male SpragueeDawley rats (Charles River Laboratory, Atsugi,
Japan) weighing about 200 g were housed under controlled light/
dark conditions (lights on: 07:00e19:00) with the room tempera-
ture regulated to 23e25 C. Rats were allowed free access to
standard rat chow (Solid rat chow, Oriental Yeast Co., Tokyo, Japan)
and tap water. All experiments were performed in conscious ani-
mals deprived of food for 24 h but with free access to water up to
the initiation of the experiments.
2.2. Chemicals
Levodopa (Tokyo Chemical Industry, Tokyo, Japan) was dis-
solved in 100% dimethyl sulfoxide (DMSO) (SigmaeAldrich, St.
Louis, MO, USA). SCH23390, a D1 dopamine receptor antagonist
and sulpiride, a D2 dopamine receptor antagonist (Wako Chemical,
Osaka, Japan), were dissolved in 100% DMSO. Synthetic orexin-A
(human/bovine/rat/mouse) was purchased from Peptide Institute
Inc., Osaka, Japan and dissolved in normal saline. Selective orexin 1
receptor (OX1) antagonist, SB334867 (Tocris Bioscience, Ellisville,
MO, USA) (12) was dissolved in 100% DMSO.
2.3. Implantation of electrodes and placement of colorectal balloon
Electrodes for measuring abdominal muscle contractions elec-
trophysiologically were acutely implanted on the day of the
experiment, as described previously (13). Brieﬂy, with the rats
under ether anesthesia, a ~5-mm incision skin was created. The
electrodes (Teﬂon coated stainless steel, 0.05 mm diameter; MT
Giken, Tokyo, Japan) were inserted approximately 2 mm into the
left side of the external oblique musculature through the incision
and ﬁxed to the incised skin with cyanoacrylate instant adhesive
(Aron Alpha, TOAGOSEI, Tokyo, Japan). The electrode leads were
externalized through this closed incision and threaded through a
urethane tube. Immediately after the implantation of electrodes, a
distension balloon was inserted intraanally with the distal end
positioned 2 cm proximal to the anus. A 6-Fr (2 mm external
diameter) disposable silicon balloon-urethral catheter for pediatric
use (JU-SB0601; Terumo, Tokyo, Japan) was used. The maximal
inﬂation volume for the balloon was 1.5 ml and the length of the
maximally inﬂated balloon was 1.2 cm. The balloon was secured in
place by taping the catheter to the tail.
2.4. Detection of visceral sensitivity
Abdominal withdrawal reﬂex (AWR) test was performed as
previously described to detect the pain threshold, which was
deﬁned as the intensity of colorectal distension that elicited AWR
(14). Tang et al. (15) have evaluated an antinociceptive effect of a
drug on visceral hypersensitivity in rats and demonstrated that the
changes in AWR score paralleled the balloon volume for colonic
distension and that intracolonic pressure was linearly associated
with intraballoon volume in the experiments. The balloon used in
the study is quite similar to the balloon used in the present study.
Al-Chaer et al. (14) have demonstrated that a stronger contraction
of the abdominal muscles in rats in response to graded colonic
distension in rats. Lifting of abdomen was consistently observed as
a characteristic of AWR and is supposed to be accompanied with a
strong contraction of the abdominal muscles (14). Visual observa-
tions of the AWR in response to graded colonic distension were a
little bit difﬁcult in Ballman cages in this study when compared on
platforms Al-Chear et al. (14) have shown. Based on these ﬁndings,we considered the threshold volume (AWR threshold volume) to
induce sudden and apparent abdominal muscle contractions
detected by EMG as a parameter for evaluating AWR as described
previously (13,16). In brieﬂy, colonic distension was performed, i.e.,
ascending method of limits phasic distension was applied by
inﬂating the balloon by water using a syringe manually until the
abdominal withdrawal reﬂex (AWR) was detected by EMG. After
completing the surgery for electrode implantation and balloon
placement as described above, the sedated rats were placed in
Ballman cages and were allowed to recover and adjust for 20 min
before testing. Then, electrode leads were connected to a custom-
made electromyogram (EMG) ampliﬁer. EMG signals were ampli-
ﬁed, ﬁltered (3000 Hz), and digitized by a PowerLab system and
recorded using a computer software (LabChart 7).
The pain threshold was assessed two times (2 min interval) and
themean of the threshold was calculated as the data of the animals.
In a large majority of the animals, the pain threshold at the ﬁrst
time was consistently equal to the second one.2.5. Experimental procedures
We initially examined the dose-related effects of subcutaneous
or intracisternal injection of levodopa on the colonic distension-
induced AWR threshold volume. Rats received subcutaneous
(0.5 ml) or intracisternal (10 ml) injections of several doses of
levodopa. Intracisternal injection was performed under brief ether
anesthesia with a 10-ml-Hamilton microsyringe after rats were
mounted in a stereotaxic apparatus (David Kopf Instruments,
Tujunga, CA) as reported previously (17). Next, to clarify whether
dopamine receptors may be involved in the levodopa-induced
antinociceptive action against colonic distension, we examined
the effect of subcutaneous injection of D1 (SCH23390, 0.2 mg/rat)
or D2 (sulpiride, 40 mg/rat) dopamine receptor antagonist on the
intracisternally administered levodopa (10 mg/10 ml) e induced
antinociceptive action against colonic distension. The doses of
dopamine receptor antagonists were selected according to the
previous report (16). To clarify whether endogenous orexin may be
involved in the levodopa-induced antinociceptive action against
colonic distension, we examined the effect of intracisternal injec-
tion of SB334867, a speciﬁc OX1R antagonist, (80 mg/10 ml) on the
subcutaneously administered levodopa-induced antinociceptive
action against colonic distension. Following the intracisternal and/
or subcutaneous injection, rats received implantation of electrodes
and placement of balloon, and were moved to Ballman cages to
evaluate the AWR threshold volume as described above. In rats
received subcutaneous and intracisternal injections, immediately
after injection of chemicals subcutaneously, we injected levodopa
intracisternally, and then completed the surgery for electrode im-
plantation and balloon placement. These procedures for each rat
were performed within 5 min.2.6. Statistical analysis
For statistical analysis of the data, data were expressed as
means ± S.E. One-way ANOVA followed by Dunnett's multiple
comparison test were used. Values of P < 0.05 were considered
statistically signiﬁcant.2.7. Ethical considerations
The approval of the Research and Development and Animal Care
committees at the Asahikawa Medical University was obtained for
all studies.
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Fig. 2. Effect of intracisternal injection of levodopa on the colonic distension-induced
abdominal withdrawal reﬂex (AWR) threshold volume in conscious rat. Each column
represents the mean ± S.E. Number of rats was 5 in each group. *P < 0.01, when
compared with control.
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Because levodopa is used as systemic administration in clinical
setting, we examined ﬁrst the effect of subcutaneous levodopa on
the colonic distension-induced visceral sensation. As demonstrated
in Fig. 1, subcutaneously administered levodopa signiﬁcantly
increased the threshold of colonic distension-induced AWR in
conscious rats. Next, the effect of intracisternal levodopa on the
visceral sensation was examined. As clearly shown in Fig. 2, intra-
cisternal levodopa dose-dependently increased the threshold of
colonic distension-induced AWR. The dose difference to induce the
antinociceptive action suggests levodopa acts centrally in the brain
to exert its antinociceptive action against colonic distension.
Next, the effects of dopamine antagonists on the levodopa-
induced antinociceptive action were examined to clarify whether
endogenous dopamine signaling may be implicated in the
levodopa-induced visceral antinociception. While neither sulpir-
ide, a D2 dopamine receptor antagonist, nor SCH23390, a D1
dopamine receptor antagonist by itself changed the threshold of
colonic distension-induced AWR, the levodopa-induced anti-
nociceptive action was signiﬁcantly blocked by pretreatment with
sulpiride but not SCH23390 (Fig. 3), suggesting that the D2 dopa-
mine receptors may mediate the levodopa-induced antinociceptive
action against colonic distension.
Finally, an effect of an OX1 antagonist on the levodopa-induced
antinociceptive action against colonic distension was investigated
to clarify whether endogenous brain orexin may play a role in the
levodopa-induced antinociception. Treatment with intracisternal
SB334867 (80 mg/10 ml) signiﬁcantly blocked the subcutaneously
administered levodopa-induced antinociceptive action while
SB334867 by itself failed to alter the threshold of AWR (Fig. 4),
suggesting that endogenous orexin may be involved in the anti-
nociceptive action by levodopa and also the levodopa-induced
antinociceptive action is exerted through central OX1 receptors.
4. Discussion
Although studies have suggested that levodopa possesses anti-
nociceptive actions against several somatic pain conditions, we do0
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Fig. 1. Effect of subcutaneous injection of levodopa on the colonic distension-induced
abdominal withdrawal reﬂex (AWR) threshold volume in conscious rat. Each column
represents the mean ± S.E. Number of rats was 5 in each group. *P < 0.01, when
compared with control.not know whether levodopa is also effective to visceral pain. The
present study was performed to clarify whether levodopa is
effective to visceral pain and its mechanisms. Subcutaneous injec-
tion of levodopa induced an antinociceptive action against colonic
distension, suggesting that levodopa is capable of inducing anti-
nociception for also visceral pain. Wang et al. (18) have demon-
strated that peripheral injection of levodopa induced Fos
expression in several brain sites such as nigrostriatal system, the
paraventricular nucleus of hypothalamus (PVN), the arcuate nu-
cleus (Arc), the central nucleus of amygdala (CeA), lateral para-
brachial nucleus (LPB), nucleus tractus solitarius (NTS) and area
postrema (AP) in rats. The NTS, the major relay center of visceral
afferents (19) is directly connected to the LPB, PVN, and CeA
(20e22). The AP receives chemical signals outside the blood-brain-
barrier and is reciprocally connected to the NTS (23), suggesting
that levodopa injected peripherally may send signals to the NTS via
the circulation. These results suggest that peripherally adminis-
tered levodopa activates a neuronal system in the central nervous
systemwhich may be related to visceral pain perception through a
direct or indirect manner. To clarify whether levodopa act directly
in the brain to induce the antinociceptive action against colonic
distension, we next examined the effect of intracisternal injection
of levodopa on visceral sensation. Because centrally injected levo-
dopa at much smaller doses when compared with doses injected
peripherally could induce the antinociceptive action against colonic
distension as seen in this study, the site of action of levodopa is
strongly considered to be within the central nervous system.
With regard to the mechanisms by which levodopa exerts its
antinociceptive action, central dopaminergic signaling may be
involved in the process because levodopa is the precursor to the
neurotransmitter dopamine and exogenously administered levo-
dopa increases dopaminergic concentrations (1). In addition, we
have very recently demonstrated that the dopamine signaling in the
brain induced an antinociceptive action against colonic distension
through D1 and D2 dopamine receptors (16). We therefore exam-
ined the involvement of dopamine receptors in the levodopa-
induced antinociception against colonic distension. As clearly
demonstrated in this study, levodopa speciﬁcally induced the
DMSO Sulpride SCH23390DMSO
DMSO ic
*
**
AW
R
 th
re
sh
ol
d 
vo
lu
m
e 
(m
l)
0
0.2
0.4
0.6
0.8
1
Levodopa ic
DMSO Sulpride SCH23390 
Fig. 3. Effect of subcutaneous injection of D1 dopamine receptor antagonist (SCH23390) or D2 dopamine receptor antagonist (sulpiride) on the intracisternally (ic) administered
levodopa-induced antinociceptive action against colonic distension in conscious rats. Each column represents the mean ± S.E. Number of rats was 5e6 in each group. *P < 0.01,
when compared with DMSO sc þ DMSO ic. **P < 0.01, when compared with DMSO sc þ levodopa ic.
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Fig. 4. Effect of intracisternal injection of SB334867, an OX1 receptor antagonist, on
the levodopa-induced antinociceptive action against colonic distension in conscious
rats. Each column represents the mean ± S.E. Number of rats was 6 in each group.
*P < 0.01, when compared with DMSO ic þ DMSO sc. **P < 0.01, when compared with
DMSO ic þ levodopa sc.
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D2dopamine receptor antagonist but not SCH23390, aD1dopamine
receptor antagonist, potentlyblocked the levodopa-inducedvisceral
antinociception. These results suggest that levodopaacts centrally in
the brain to induce antinociceptive action against colonic distension
through activation of dopamine D2 receptors.
Decreased dopamine signaling plays a key role in the patho-
physiology of PD (24). Long-term levodopa use is associated with
the “End of Dose Wearing Off” (EODWO) phenomenon wherein
Parkinsonian symptoms return before a patient's next scheduled
dose of levodopa. Abdominal pain is an important wearing off
symptom as an early indicator of the development of EODWO in PD
patients (25), suggesting that reduced dopamine signaling might
induce visceral hypersensitivity. The present ﬁnding that levodopa
evoked a visceral antinociceptive action via the dopamine signaling
may explain the mechanism by which abdominal pain is consid-
ered as EODWO phenomenon in PD patients.
Orexins are neuropeptides that are localized to neurons in the
lateral hypothalamus (26,27). Despite their highly restricted origin,
orexin nerve ﬁbers have been identiﬁed throughout the centralnervous system (28,29), suggesting that activation of orexin
signaling modulates various biological systems. Increasing evi-
dence has demonstrated that orexin-A acts centrally to regulate
gastrointestinal functions such as gastric secretion and gastroin-
testinal motility (30e34). In addition, we have very recently
demonstrated that not only exogenously administered but also
endogenously released orexin in the brain induces an anti-
nociceptive action against colonic distension in conscious rats (13),
indicating a role of brain orexin in the regulation of visceral
sensation. We therefore made a hypothesis that endogenous orexin
in the brain may mediate the levodopa-induced antinociceptive
action against colonic distension. To clarify the hypothesis, the ef-
fect of intracisternal SB334867, a speciﬁc OX1 receptor antagonist
on the subcutaneous levodopa-induced antinociceptive action
against colonic distension was examined. As clearly shown in this
study, SB334867 signiﬁcantly blocked the levodopa-induced anti-
nociceptive action against colonic distension, suggesting that
endogenous orexin in the brain mediates the levodopa-induced
antinociceptive action through OX1 receptors.
SB334867 should be injected centrally to block the brain orexin
action as reported previously (13). On the other hand, the dopa-
mine antagonists used in the present study could be injected
peripherally to block the brain dopaminergic signaling as reported
previously (17). Since we considered that two chemicals should be
administered via different routes (intracisternal and subcutaneous)
to rule out unexpected reactions when injected via a same intra-
cisternal route, we selected the injection routes as shown in this
study. Not only intracisternal but also subcutaneous levodopa is
capable of inducing an antinociceptive action as shown in the
present study, we planned the experimental protocol to examine
the effects of dopamine antagonists or the orexin antagonist on the
levodopa-induced visceral antinociception. Levodopa was there-
fore injected intracisternally in Fig. 3 while levodopa was admin-
istered subcutaneously in Fig. 4.
We have recently demonstrated that not only dopamine D2
receptor agonist but also dopamine D1 agonist could induce an
antinociceptive action against colonic distension in rats, suggesting
that dopamine is capable of inducing antinociception through
dopamine D1 and D2 receptors (17). We have furthermore reported
that centrally injected orexin-A induces antinociceptive action
against colonic tension is blocked by either dopamine D1 or D2
T. Okumura et al. / Journal of Pharmacological Sciences 130 (2016) 123e127 127receptor antagonist, suggesting that both dopamine D1 and D2
receptors mediate the centrally injected orexin-A-induced visceral
nociception (17). On the other hand, the present results demon-
strated that the antinociceptive action by levodopa was signiﬁ-
cantly blocked by SB334867, an orexin 1 receptor antagonist, or
dopamine D2 receptor antagonist, but not D1 antagonist. The
discrepancy may be explained by following speculation. Endoge-
nously released orexin in the brain induced by levodopa may
preferentially activate the D2 dopamine signaling while exoge-
nously administered orexinmay activate equally both dopamine D1
and D2 receptors signaling. Further studies should be needed to
clarify the speculation.
We have very recently demonstrated that the dopamine
signaling in the brain induced an antinociceptive action against
colonic distension and the dopamine signaling may mediate the
brain orexin-induced antinociception (16). In turn, the present
ﬁndings indicate that endogenous orexin may mediate the
levodopa-induced antinociception. Levodopa is the precursor to the
neurotransmitter dopamine and exogenously administered levo-
dopa increases dopaminergic concentrations (1). In addition, the
present study clearly showed that the dopamine D2 receptor
antagonist blocked the levodopa-induced antinociception, sug-
gesting that the endogenous dopamine signaling is involved in the
antinociceptive process by levodopa. Based on these ﬁndings, we
would propose a hypothesis that dopamine and orexin may act
bidirectionally in each other in the brain to induce an anti-
nociceptive action against colonic distension. It would be further-
more speculated that levodopa is capable of inducing a visceral
antinociceptive action through activation of the bidirectional
dopamine and orexinergic signaling circuit. The above speculation
could explain the present ﬁndings that the dopamine receptor
antagonist or the orexin receptor antagonist signiﬁcantly blocked
the levodopa-induced visceral antinociception.
In conclusion, the present study clearly demonstrated that
levodopa acts centrally to induce a visceral antinociception through
activation of D2 dopamine receptors and the orexinergic system in
the brain.Conﬂict of interest
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